EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Assessment of Cancer‐Related Cognitive Impairments Across Anti‐Cancer Therapies in a Predominantly Breast Cancer Cohort

Qiqi Lei iD, Martina E Schmidt iD, Philipp Zimmer iD, Patric Meyer, Andreas Schneeweiss iD, Karen Steindorf iD

International Journal of Cancer · 01.01.2027 · 160 (1) · 85-97

DOI: 10.1002/ijc.70691 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 07.08.2026. Verfasst von Qiqi Lei und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Physical Activity, Cancer Prevention and Survivorship, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT) …. Hauptthemen laut MEDLINE: Breast Neoplasms, Chemotherapy-Related Cognitive Impairment, Antineoplastic Agents, Cognitive Dysfunction. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer survivors frequently experience cancer‐related cognitive impairment (CRCI), but the contributions of different anti‐cancer therapies remain unclear. Patients with breast or gynaecological cancer were recruited before any anti‐cancer treatment. Cognitive function was assessed by objective and subjective measures pre‐treatment (T0), post‐treatment (T1), and 1 year after T1 (T2). Objective measures include Hopkins Verbal Learning Test‐Revised (HVLT‐R), Trail Making Test (TMT), Controlled Oral Word Association Test (COWA), and Mnemonic Similarity Task (MST). Subjective measures include Functional Assessment of Cancer Therapy—Cognitive scale (FACT‐Cog) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ‐C30). Linear mixed models were performed. Patients ( n = 234) were of age 55.4 ± 11.6 years. At T1, chemotherapy was associated with worse visual searching and motor speed (TMT‐A: β = 0.36, 95% CI: 0.03–0.69), perceived global function (FACT‐Cog Global Function: β = −0.39, 95% CI: −0.67 to −0.11), and cognitive function (EORTC QLQ‐C30: β = −0.50, 95% CI: −0.82 to −0.18) compared to endocrine therapy. At T2, endocrine therapy was associated with poorer verbal learning and memory performance (HVLT‐R total recall: β = −0.40, 95% CI: −6 to −0.03) and higher perceived cognitive impairments (FACT‐Cog PCI: β = 0.34, 95% CI: 0.05–0.63). In conclusion, CRCI may occur during certain types of chemotherapy but appears to ameliorate over time. Ongoing endocrine therapy may have longer‐lasting impact on cognitive function. Appropriate counselling for informed decision making and good supportive care is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsChemotherapy-Related Cognitive ImpairmentAntineoplastic AgentsCognitive DysfunctionHumansFemaleMiddle AgedAgedQuality of LifeNeuropsychological TestsAdultCohort StudiesCognition

Stichwörter der Autor:innen

breast cancercancer survivorshipcancer‐related cognitive impairmentchemotherapyendocrine therapy

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Division of Physical Activity, Cancer Prevention and Survivorship, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT) Heidelberg, a Partnership Between DKFZ and University Medical Center H…
  • Medical Faculty, University of Heidelberg, Heidelberg, Germany.
  • Division of Sports Medicine, Institute for Sport and Sport Science, TU Dortmund University, Dortmund, Germany.
  • School of Psychology, SRH University of Applied Sciences Heidelberg, Heidelberg, Germany.
  • Department for General and Applied Linguistics, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany.
  • Network Aging Research (NAR), Ruprecht-Karls-University Heidelberg, Heidelberg, Germany.

ORCID-Profile: Qiqi Lei, Martina E Schmidt, Philipp Zimmer, Andreas Schneeweiss, Karen Steindorf

Zitieren

APA

Lei, Q., Schmidt, M. E., Zimmer, P., Meyer, P., Schneeweiss, A., & Steindorf, K. (2027). Assessment of Cancer‐Related Cognitive Impairments Across Anti‐Cancer Therapies in a Predominantly Breast Cancer Cohort. International Journal of Cancer, 160(1), 85-97. https://doi.org/10.1002/ijc.70691

Vancouver

Lei Q, Schmidt ME, Zimmer P, Meyer P, Schneeweiss A, Steindorf K. Assessment of Cancer‐Related Cognitive Impairments Across Anti‐Cancer Therapies in a Predominantly Breast Cancer Cohort. International Journal of Cancer. 2027;160(1):85-97. doi:10.1002/ijc.70691

BibTeX
@article{Lei2027,
  author = {Lei, Qiqi and Schmidt, Martina E and Zimmer, Philipp and Meyer, Patric and Schneeweiss, Andreas and Steindorf, Karen},
  title = {Assessment of Cancer‐Related Cognitive Impairments Across Anti‐Cancer Therapies in a Predominantly Breast Cancer Cohort},
  journal = {International Journal of Cancer},
  year = {2027},
  volume = {160},
  number = {1},
  pages = {85--97},
  doi = {10.1002/ijc.70691}
}
Kostenlos starten →